Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.63 |
| ▸ | TTR | P02766 | 1/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.63 |
| ▸ | AHR | P35869 | 1/20 | 0.62 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3,4,5-Trihydroxy-Transstilbene SCHEMBL41160 | 1.00 | PTGS2 (0.63) | PTGS2PTGS1TTRALOX5AHR | |
| SCHEMBL15542754 | 0.87 | PTGS2 (0.55) | PTGS2PTGS1TTRALOX5AHR | |
| SCHEMBL15542753 | 0.87 | PTGS2 (0.55) | PTGS2PTGS1TTRALOX5AHR | |
| (Z)-1,2-Diphenylethene SCHEMBL27882852 | 0.87 | PTGS2 (0.55) | PTGS2PTGS1TTRALOX5AHR | |
| SCHEMBL4608754 | 0.84 | PTGS2 (0.54) | PTGS2PTGS1TTRALOX5TUBB1 | |
| SCHEMBL4608757 | 0.84 | PTGS2 (0.54) | PTGS2PTGS1TTRALOX5TUBB1 | |
| SCHEMBL3645729 | 0.82 | TUBB1 (0.70) | PTGS2PTGS1TTRALOX5AHR | |
| SCHEMBL3645732 | 0.82 | TUBB1 (0.70) | PTGS2PTGS1TTRALOX5AHR | |
| SCHEMBL2718303 | 0.82 | TUBB1 (0.70) | PTGS2PTGS1TTRALOX5AHR | |
| SCHEMBL10597010 | 0.82 | PTPN1 (0.71) | PTGS2PTGS1TTRALOX5AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014039011-A1 | METHODS TO INHIBIT INTRACELLULAR GROWTH OF BACTERIA AND TO TREAT BACTERIA-MEDIATED DISEASES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-03-13 | — | — | WO | claimed |
| US-20060286046-A1 | Skin care compositions | HABER C ANDREW | 2006-12-21 | — | — | US | claimed |
| WO-2006072175-A1 | SKIN CARE COMPOSITIONS | HABER DERMACEUTICS INC. (CA) | 2006-07-13 | — | — | WO | claimed |
| US-20050020511-A1 | Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus | BEIJING LUYIN LIHUA PHARMACEUTICAL SCIENCE AND TECHNOLOGY DEVELOPMENT COMPANY LTD (CN) | 2005-01-27 | — | — | US | claimed |
| EP-1421933-A1 | USE OF STILBENE COMPOUNDS IN PREPARING MEDICAMENTS FOR TREATING OR PREVENTING DIABETES AND DISEASES ASSOCIATED WITH RETROVIRUS | Institute of Radiation Medicine, Academy of Military Medical Sciences Pla (CN) | 2004-05-26 | — | — | EP | claimed |
| EP-1280556-A1 | COMPOSITIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2003-02-05 | — | — | EP | claimed |
| WO-2001085142-A1 | COMPOSITIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2001-11-15 | — | — | WO | claimed |
| CN-122012264-A | Yarrowia lipolytica BS-3 and application thereof in resveratrol production | 杭州精构生物科技有限责任公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12515955-B2 | Carbon material, use thereof in batteries, method for producing said material and electrode comprising same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2026-01-06 | — | — | US | disclosed |
| WO-2025224591-A1 | ORAL PRODUCT WITH FLAVOR EMULSION | Nicoventures Trading Limited (GB) | 2025-10-30 | — | — | WO | disclosed |
| EP-3943071-B1 | COMPOSITION COMPRISING NATURAL LIPOPHILIC COMPOUNDS, USE OF THE COMPOSITION AND METHOD FOR PREPARING THE COMPOSITION | KHINIKADZE ZURAB DURMISCHCHANOWITCH (RU) | 2025-06-18 | — | — | EP | disclosed |
| CN-119837847-A | Application of resveratrol in preparation of products for preventing and/or treating recurrent abortion caused by unknown reasons | 安徽医科大学第一附属医院 | 2025-04-18 | — | — | CN | disclosed |
| CN-119033705-B | Preparation method and application of GelMA Cryogel microsphere carrying resveratrol nanocrystal | 吉林大学 | 2025-02-11 | — | — | CN | disclosed |
| EP-1280556-A1 | COMPOSITIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2003-02-05 | — | — | EP | disclosed |
| CN-1385535-A | Method for raising Resveratrol content in Chinese herb-giant knotweed rhizome | SHENZHEN QINGHUA MORDERN CHINE (CN) | 2002-12-18 | — | — | CN | disclosed |
| WO-2001091695-A2 | THE USE OF RESVERATROL AS SUNSCREEN | D.B.P. DI ROSSI VALENTINA E C. S.N.C. (IT) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001091714-A1 | USE OF STILBENE DERIVATIVES FOR DANDRUFF TREATMENT | D.B.P. DI ROSSI VALENTINA E C. S.N.C. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001085142-A1 | COMPOSITIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2001-11-15 | — | — | WO | disclosed |
| US-5087548-A | POSITIVE TYPE RADIATION-SENSITIVE RESIN COMPOSITION | JAPAN SYNTHETIC RUBBER CO., INC. (JP) | 1992-02-11 | — | — | US | disclosed |
| EP-0227487-A2 | Positive type radiation-sensitive resin composition | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020511-A1 | Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus | POT1, SLC5A1, VHL | PTGS2 2391/4885PTGS1 607/4885TTR 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.